<DOC>
	<DOCNO>NCT02066220</DOCNO>
	<brief_summary>The study PNET 5 MB design child medulloblastoma standard risk ( accord risk-group definition use far ; e.g . PNET 4 ) . With advent biological parameter stratification clinical medulloblastoma trial , ß-catenin status criterion accord study patient assign either treatment arm PNET 5 MB - LR PNET 5 MB - SR , respectively . The initial diagnostic assessment ( image , stag , histology , tumor biology ) require study entry treatment arm .</brief_summary>
	<brief_title>International Society Paediatric Oncology ( SIOP ) PNET 5 Medulloblastoma</brief_title>
	<detailed_description>The aim LR-treatment arm confirm high rate event-free survival patient age 3 5 year less 22 , 'standard risk ' medulloblastoma low-risk biological profile . Patients eligible study non-metastatic medulloblastoma ( CSF cytology centrally review MRI image ) diagnosis low-risk biological profile , define ß-catenin nuclear immuno-positivity immuno-histochemistry ( IHC ) . Patients undergone total near-total tumour resection receive conventionally fractionate ( day ) radiotherapy dose 54 Gy primary tumor 18.0 Gy craniospinal axis . Following radiotherapy , patient receive reduced-intensity chemotherapy total 6 cycle chemotherapy consist 3 course cisplatin , CCNU vincristine alternate 3 course cyclophosphamide vincristine . The aim SR-arm test whether concurrent carboplatin radiotherapy follow 8 cycle maintenance chemotherapy patient 'standard risk ' medulloblastoma average-risk biological profile may improve outcome . Patients eligible study non-metastatic medulloblastoma ( CSF cytology centrally review MRI image ) diagnosis average-risk biological profile , define ß-catenin nuclear immuno-negativity IHC . Patients undergone total near-total tumour resection receive conventionally fractionate ( day ) radiotherapy dose 54 Gy primary tumor 23.4 Gy craniospinal axis . Following radiotherapy , patient receive modified-intensity chemotherapy total 8 cycle chemotherapy consist 4 course cisplatin , CCNU vincristine alternate 4 course cyclophosphamide vincristine .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Age diagnosis , least 3 5 year ( depend country ) less 22 year ( LRarm : le 16 year ) . The date diagnosis date surgery undertaken . 2 . Histologically proven medulloblastoma , include follow subtypes , define WHO classification ( 2007 ) : classic medulloblastoma , desmoplastic/nodular medulloblastoma . Pretreatment central pathology review consider mandatory . 3 . Standardrisk medulloblastoma , define ; total near total surgical resection less equal 1.5 cm2 ( measure axial plane ) residual tumour early postoperative MRI , without contrast , central review ; central nervous system ( CNS ) metastasis MRI ( cranial spinal ) central review ; tumour cell cytospin lumbar CSF clinical evidence extraCNS metastasis ; Patients reduction postoperative residual tumor second surgery less equal 1.5 cm2 eligible , timeline start radiotherapy keep . 4 . Submission high quality biological material include fresh frozen tumor sample molecular assessment biological marker ( assessment myelocytomatosis oncogene ( MYC ) copy number status ) national biological reference center . Submission blood mandatory patient , agree germline DNA study . Submission CSF recommend . 5 . No amplification MYC MYCN ( determined FISH ) . 6 . For LRarm : Lowrisk biological profile , define WNT subgroup positivity . The WNT subgroup define presence ( ) ßcatenin mutation ( mandatory testing ) , ( ii ) ßcatenin nuclear immunopositivity IHC ( mandatory test ) ßcatenin mutation , ( iii ) ßcatenin nuclear immunopositivity IHC monosomy 6 ( optional testing ) . For SRarm : averagerisk biological profile , define ßcatenin nuclear immunonegativity IHC ( mandatory ) mutation analysis ( optional ) . 7 . No prior therapy medulloblastoma surgery . 8 . Radiotherapy aim start 28 day surgery . Foreseeable inability start radiotherapy within 40 day surgery render patient ineligible study . 9 . Screening compliance eligibility criterion complete , patient include study within 28 day first surgery ( case second surgery within 35 day first surgery ) . Inclusion patient possible later 40 day first tumour surgery , start radiotherapy . 10 . Common toxicity criterion ( CTC ) grade &lt; 2 liver , renal , haematological function 11. significant sensorineural hearing deficit define pure tone audiometry bone conduction air conduction normal tympanogram showing impairment ≥ 20 decibel ( dB ) 13 kilohertz ( kHz ) . If performance pure tone audiometry possible postoperatively , normal otoacoustic emission acceptable , history hearing deficit . 12 . No medical contraindication radiotherapy chemotherapy , preexist DNA breakage syndrome ( e.g . Fanconi Anemia , Nijmegen breakage syndrome ) , Gorlin Syndrome reason define patient 's clinician . 13 . No identified Turcot Li Fraumeni syndrome . 14 . Written informed consent ( patient assent appropriate ) therapy accord law participate country . Information must provide patient biological study ( tumour germline ) , write informed consent obtain agreement participation . 15 . National local ethical committee approval accord law participate country ( include approval biological study ) . 1 . One inclusion criterion lack . 2 . Brainstem supratentorial primitive neuroectodermal tumour . 3 . Atypical teratoid rhabdoid tumour . 4 . Medulloepithelioma ; Ependymoblastoma 5 . Largecell medulloblastoma , anaplastic medulloblastoma , medulloblastoma extensive nodularity ( MBEN ) , centrally confirm . 6 . Unfavourable undeterminable biological profile , define amplification MYC MYCN , MYC MYCN WNT subgroup status determinable . 7 . Metastatic medulloblastoma ( CNS MRI and/or positive cytospin postoperative lumbar CSF ) . 8 . Patient previously treat brain tumour type malignant disease . 9 . DNA breakage syndrome ( e.g . Fanconi anemia , Nijmegen breakage syndrome ) , identify Gorlin , Turcot , Li Fraumeni syndrome . 10 . Patients pregnant . 11 . Female patient sexually active take reliable contraception . 12 . Patients regularly follow due psychological , social , familial geographic reason . 13 . Patients noncompliance toxicity management guideline expect .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pediatric brain tumor</keyword>
	<keyword>medulloblastoma</keyword>
	<keyword>event-free survival ( EFS )</keyword>
	<keyword>progression-free survival ( PFS )</keyword>
	<keyword>overall survival ( OS )</keyword>
	<keyword>PNET</keyword>
	<keyword>posterior fossa</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>biological profile</keyword>
	<keyword>ß-catenin</keyword>
</DOC>